WHC est encore en dévelopement. Lisez ceci pour comprendre notre approche.
depiction of DQCKKXVULJGBQN-UHFFFAOYSA-N.svg
isomerdesign

17-(Cyclopropylmethy...

Vérifier sur isomerdesign

pubchem

Naltrexone

Vérifier sur pubchem

drugmap

Naltrexone

Vérifier sur drugmap

wiki

Naltrexone

Vérifier sur wiki

Data

InChI: InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2

Synonymes: naltrexone,UM-792, Naltrexone depot (injectable suspension), elbion,NALTREXONE [ORANGE BOOK],5S6W795CQM, Vivitrex,NALTREXONE [HSDB],Naltrexone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,DSSTox_RID_81532, Naltrexone depot (injectable suspension), DrugAbuse Sciences,Vivitrex,NALTREXONE COMPONENT OF CONTRAVE, XR-NTX,Naltrexone [USAN:INN:BAN],Prestwick0_000116, PTI-901,PDSP2_000847,Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)-,N-Cyclopropylmethylnoroxymorphone,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one,MFCD00242996,Vivitrol,NALTREXONE [MART.],BCP07022, Naltrel,EN-1639A [AS HYDROCHLORIDE],BRN 3596648,NALTREXONE [MI],Naltrexonum,NCGC00024427-04,(-)-Naltrexone,C07253, Opioid antagonists (irritable bowel syndrome), Pain Therapeutics,CAS-16590-41-3,16590-41-3,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one,(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one,(4R,4As,7aR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one, Naltrexone (once-monthly controlled-release, Medisorb), Alkermes,Naltrexone base anhydrous,PTI-555,cyclopropylmethyl(dihydroxy)[?]one,ZINC1773, IBS therapy, Pain Therapeutics,NCGC00024427-05,HSDB 6750,DSSTox_CID_26313,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride,AB00174152_17,NSC-758439, Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek, Naltrexone (sustained release), DAS,17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5α-epoxymorphinan-6-one,NALTREXONE [USAN],17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one,4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-trien-14-one,cid_5485201,NCGC00024427-03,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-bis(oxidanyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride,Naltrexone (USAN/INN),Naltrexonum [INN-Latin],(-)naltrexone,CCRIS 3506,17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one,CHEMBL19019,Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-,EINECS 240-649-9,NALTREXONE [WHO-DD],Prestwick2_000116,Naltrexona [INN-Spanish], Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma, Naltrexone (low-dose), Pain Therapeutics,AB00174152-14,BIDD:GT0405,SPBio_002071,BPBio1_000146,BRD-K88172511-003-21-1,BSPBio_000132, Naltrexone (sustained release), elbion,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one,ReVia,NCGC00162274-02,17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxmorphinan-6-one, (5.alpha.)-,Tox21_112007_1,Celupan,SCHEMBL34681,DSSTox_GSID_46313,BDBM50000787,NALTREXONE [USP-RS],D05113,BDBM60212,N-Cyclopropylmethyl-14-hydroxydihydromorphinone,NALTREXONE [VANDF], Irritable bowel syndrome therapy, Pain Therapeutics,US9107954, naltrexone,Prestwick3_000116,BRD-K88172511-310-03-8,Depotrex,Naltrexona,UNII-5S6W795CQM,Nemexin,EN-1639A FREE BASE,DTXSID4046313,SMP1_000206,Tox21_112007,AKOS015994596,GTPL1639,CS-0880,HMS2089O11,Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-,HY-76711,HS-0002,CHEBI:7465,Prestwick1_000116,EX-A4863,EN300-19748946,Vivitrol (TN),AC-36726,(5α)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one, Naltrexone Depot,(4R,4aS,7aR,12bS)-3-(Cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinolin-7(7aH)-one,NSC 758439,DB00704,Q409587, Vivitrol,AR-270/43507956,NALTREXONE [INN],3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one

Estimated data

Solubility: -3.122 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 57.7% (prediction based on www.mdpi.com)

Similitudes

Voici une série de comparaisons visant à comprendre les propriétés de ce composé. Ce site est encore très expérimental et fait l'objet d'un développement actif. Veuillez vous référer à notre série d'articles d'articles pour bien comprendre notre approche et ses limites. Ces informations sont données à titre indicatif et ne doivent pas être interprétées comme des conseils médicaux.